Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

128.20
Delayed Data
As of 4:00pm ET
 -2.69 / -2.06%
Today’s Change
35.98
Today|||52-Week Range
147.63
+242.41%
Year-to-Date
No recent news for Alnylam Pharmaceuticals Inc.

Today’s Trading

Previous close130.89
Today’s open131.72
Day’s range126.40 - 132.24
Volume929,078
Average volume (3 months)1,392,547
Market cap$12.9B
Dividend yield--
Data as of 4:00pm ET, 12/11/2017

Growth & Valuation

Earnings growth (last year)-38.84%
Earnings growth (this year)-11.56%
Earnings growth (next 5 years)+152.00%
Revenue growth (last year)+14.75%
P/E ratioNM
Price/Sales67.96
Price/Book12.22

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc-0.72-1.36%
SGENSeattle Genetics Inc-3.99-6.74%
TSROTESARO Inc-2.37-2.81%
JAZZJazz Pharmaceuticals...+1.03+0.74%
Data as of 4:00pm ET, 12/11/2017

Financials

Next reporting dateFebruary 8, 2018
EPS forecast (this quarter)-$1.38
Annual revenue (last year)$47.2M
Annual profit (last year)-$410.1M
Net profit margin-869.63%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts